Research in the Asara lab focuses on developing approaches to personalized medicine by analyzing cancer cells and tumor samples in order help make appropriate therapeutic decisions with "smart" drugs. The data are generated from a single liquid-liquid extraction from a biological sample for various omics, a process that we term "serial-omics". These integrated datasets provide insight into how kinase signaling communicates with metabolic processes. We are also developing hypothesis directed strategies to understand the fundamental drivers of disease in cancers such as multiple myeloma, lung cancer and prostate cancer by performing protein-protein interaction studies, immunoprecipitation (IP)-tandem mass spectrometry (MS/MS), quantitative phosphoproteomics, 13C/15N metabolic flux analyses with stable isotope labeling and lipidomics profiling. In addition to our internal research, we are involved in many collaborative projects that are coordinated through our state-of-the-art mass spectrometry technologies and services through our mass spectrometry facility. We have demonstrated that these techniques can be applied to any biological source including tumor tissue, cells culture, dried blood spots, urine, hair, etc.